News
DSGN
13.74
+0.29%
0.04
Weekly Report: what happened at DSGN last week (0615-0619)?
Weekly Report · 1d ago
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), SAB Biotherapeutics (SABS) and Design Therapeutics (DSGN)
TipRanks · 06/15 11:50
Weekly Report: what happened at DSGN last week (0608-0612)?
Weekly Report · 06/15 10:03
Design Therapeutics Stockholders Approve Director and Auditor at Meeting
TipRanks · 06/11 21:13
Design Therapeutics shareholders elect Simeon George to board at annual meeting
PUBT · 06/11 20:05
Weekly Report: what happened at DSGN last week (0601-0605)?
Weekly Report · 06/08 10:00
Acting FDA head vows to block political interference, Endpoint News says
TipRanks · 06/04 18:16
FDA issues draft guidance to help accelerated cell, gene therapies for patients
TipRanks · 06/02 14:03
Weekly Report: what happened at DSGN last week (0525-0529)?
Weekly Report · 06/01 10:03
Design Therapeutics management to join Jefferies Global Healthcare Conference fireside chat
PUBT · 05/28 12:06
Piper Sandler Reaffirms Their Buy Rating on Design Therapeutics (DSGN)
TipRanks · 05/27 11:38
AZN, Daiichi's Datroway Wins FDA Nod for Expanded Use in Breast Cancer
NASDAQ · 05/25 15:30
Weekly Report: what happened at DSGN last week (0518-0522)?
Weekly Report · 05/25 10:05
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On Wednesday
Benzinga · 05/20 14:02
Analysts Conflicted on These Healthcare Names: Design Therapeutics (DSGN), Pro Medicus Limited (OtherPMCUF) and Boston Scientific (BSX)
TipRanks · 05/20 01:50
Notable Tuesday Option Activity: AEVA, RKLB, DSGN
NASDAQ · 05/19 19:19
Analysts’ Top Healthcare Picks: Neuren Pharmaceuticals Limited (NURPF), Design Therapeutics (DSGN)
TipRanks · 05/19 13:20
Design Therapeutics Down Over 25%, on Track for Largest Percent Decrease Since August 2023 -- Data Talk
Dow Jones · 05/18 18:33
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data
Benzinga · 05/18 18:26
Crude Oil Gains Over 2%; US Homebuilder Sentiment Increases In May
Benzinga · 05/18 18:25
More
Webull provides a variety of real-time DSGN stock news. You can receive the latest news about Design Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About DSGN
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.